Loading...
NPI 1265683049 · Santa Fe, NM · Community/Behavioral Health Agency
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
New Mexico Treatment Services LLC is a community/behavioral health agency provider located in Santa Fe, New Mexico. This profile covers 2 Medicare and 11 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | New Mexico Treatment Services LLC |
| Address | 1264 Rodeo Rd |
| City | Santa Fe |
| State | NM |
| ZIP | 87505 |
| Taxonomy | Community/Behavioral Health Agency |
| NPI Enumerated | October 10, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $35.3M |
| Medicare | $291.6K |
This entity is effectively Medicaid-centric in scale: Total Medicare revenue is $291.6K while Total Medicaid revenue is $35.3M, so the vast majority of billed dollars come from Medicaid rather than Medicare. Analysts should treat Medicaid patterns as the primary driver of the business profile and financial risk exposure.
The provider’s service mix is characteristic of an opioid treatment program and community behavioral health agency: high-volume methadone administration codes (H0020 on Medicaid and G2067 on Medicare) plus counseling, comprehensive medication services (H2010), and routine toxicology screening (80307) dominate the coding. This combination of dispensing, counseling/therapy, and testing points to an operation focused on medication-assisted treatment (methadone and buprenorphine) and associated behavioral-health support.
Medicare billing is highly concentrated: the precomputed top 3 Medicare codes by revenue account for 100.0% of the provider's total Medicare revenue, and G2067 alone represents $281.3K (96.6% of Medicare revenue). That concentration indicates Medicare activity is essentially limited to the weekly methadone bundle rather than a broader mix of E/M or ancillary services.
Medicaid revenue is also highly concentrated, with the precomputed top 3 Medicaid codes by revenue accounting for 97.5% of total Medicaid revenue. In particular H0020 accounts for $29.4M (83.5% of Medicaid revenue) across 1.7M claims at $17 avg paid/claim, and it ranks #1 of 16 providers in-state (100th percentile; notably above typical state volume), indicating dominance of methadone administration in the provider’s Medicaid book.
The provider’s competitive standing is mixed by payer: nationally, Medicare volume for G2067 is modest — G2067 ranks #189 of 830 providers (77th percentile; described as typical, unremarkable volume), whereas within New Mexico the provider is a clear leader for methadone services on Medicaid. This suggests the organization is a major state-level OTP for Medicaid beneficiaries but only a routine participant in the national Medicare OTP cohort.
Ancillary Medicaid services contribute meaningful secondary revenue streams and operational signals: 80307 (drug testing) accounts for $3.6M (10.2% of Medicaid revenue) with 61.1K claims and ranks #5 of 77 in-state (95th percentile; notably above typical state volume), and H0025 (prevention education) contributes $1.3M (3.8% of Medicaid revenue). High volumes of testing and prevention/education codes are consistent with an OTP that couples medication dispensing with monitoring and population-level outreach.
Operational scale differs greatly between payers and by code: the provider submitted 1.7M Medicaid H0020 claims versus 1.2K Medicare G2067 claims, reflecting enormous differences in encounter counts and payer engagement. For analysts this signals operational capacity centered on high-frequency, low-dollar Medicaid dispensing activity rather than low-frequency, higher-dollar Medicare outpatient encounters.
The NPI was enumerated on 2008-10-10 (~18 years ago), indicating long tenure in the market; combined with the high Medicaid H0020 volume and top-in-state rank, this tenure supports the interpretation of an established opioid treatment program with sustained state-level reach. Additionally, some medication codes (J0571 and J0575) appear but lack meaningful in-state peer comparisons (e.g., J0571 ranks #1 of 1 providers in-state; 0th percentile; no state peer volume comparison available), so certain medication-prescribing patterns may be unique or limited in peer-context data.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 1,220 | $230 | $281.3K |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | 270 | $40 | $9.9K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 2 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 1,729,640 | $20 | $29.4M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 61,140 | $60 | $3.6M |
| H0025 | Behavioral health prevention education service (delivery of services with target population to affect knowledge, attitude and/or behavior) | 22,240 | $60 | $1.3M |
| H2010 | Comprehensive medication services, per 15 minutes | 15,640 | $30 | $453.6K |
| J0571 | Buprenorphine, oral, 1 mg | 32,790 | $10 | $262.3K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,310 | $70 | $85K |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | 1,790 | $20 | $32.2K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 120 | $120 | $13.3K |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 140 | $90 | $13K |
| H0001 | Alcohol and/or drug assessment | 100 | $70 | $6.4K |
Showing 1–10 of 11
How this provider's Medicaid billing volume and revenue compare to other New Mexico providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New Mexico median
11 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 1 | 20 | 290,440 | $20 | $12.3M |
| H0025 | Behavioral health prevention education service (delivery of services with target population to affect knowledge, attitude and/or behavior) | 3 | 20 | 7,950 | $80 | $839K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 5 | 80 | 3,340 | $60 | $595K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 405 | 930 | 910 | $80 | $521.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 778 | 960 | 1,010 | $90 | $490K |
| H2010 | Comprehensive medication services, per 15 minutes | 3 | 10 | 920 | $60 | $298.7K |
| 99212 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a straightforward level of medical decision making,… | 302 | 380 | 220 | $160 | $273.9K |
| J0571 | Buprenorphine, oral, 1 mg | 1 | 10 | 32,790 | $10 | $265.5K |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | 1 | 10 | 1,790 | $20 | $32.6K |
| H0001 | Alcohol and/or drug assessment | 9 | 10 | 110 | $50 | $26K |
Showing 1–10 of 11
Other providers in the same ZIP code as New Mexico Treatment Services LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.